alexa Neoadjuvant Vemurafenib for Borderline Resectable Metastatic Melanoma to Liver: A Case Report | Open Access Journals
ISSN: 2157-2518
Journal of Carcinogenesis & Mutagenesis
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Neoadjuvant Vemurafenib for Borderline Resectable Metastatic Melanoma to Liver: A Case Report

Yifei Sun1, James Beattie2, Harveshp Mogal1 and Eddy C. Hsueh1*

1 Division of General Surgery, Department of Surgery, Saint Louis University, Missouri, USA

2 SSM Cancer CareSt. Louis, Missouri, USA

*Corresponding Author:
Eddy C. Hsueh
Department of Surgery
Saint Louis University
3635 Vista at Grand Blvd
St. Louis, Missouri 63110, USA
Tel: 1-314-577-8566
Fax: 1-314-771-1945
E-mail: [email protected]

Received date: March 22, 2014; Accepted date: April 22, 2014; Published date: April 29, 2014

Citation: Sun Y, Beattie J, Mogal H, Hsueh CE (2014) Neoadjuvant Vemurafenib for Borderline Resectable Metastatic Melanoma to Liver: A Case Report. J Carcinog Mutagen 5:169. doi: 10.4172/2157-2518.1000169

Copyright: © 2014 Sun Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Carcinogenesis & Mutagenesis

Abstract

Vemurafenib is a selective inhibitor of mutated B-Raf protein, which is found in 60% of metastatic melanoma. Neoadjuvant Vemurafenib for patient with metastatic melanoma, to decrease tumor size prior to surgical resection has been reported in patients with metastatic melanoma to the brain and lymph nodes. We present a case of neoadjuvant Vemurafenib in a patient with large borderline resectable metastatic melanoma to the liver.

Keywords

Vemurafenib; Metastatic melanoma; Liver

Introduction

About 60% of metastatic melanoma tumors were found to have mutated B-Raf protein, which is a serine/threonine-protein kinase in the B-Raf/MEK/ERK pathway controlling cell division and differentiation [1]. The most common B-Raf mutation is at amino acid position 600, in which the normal valine is replaced by glutamic acid (B-Raf V600E mutation). The mutation causes the B-Raf gene to be constitutively activated to signal excessive cell growth [2]. Vemurafenib is a selective inhibitor of the active form of B-Raf [3]. Vemurafenib has been shown to cause programmed cell death in melanoma cell lines [4] and has been shown to improve survival in patients with metastatic melanoma with B-Raf V600E mutation [5].

Neoadjuvant Vemurafenib has been reported in patients with metastatic melanoma to the brain and lymph nodes [6]. We present a case of Vemurafenib neoadjuvant therapy prior to surgical resection in a patient with large borderline resectable metastatic melanoma to the liver and retroperitoneal lymph nodes.

Case Report

A 63 year old white male with history of posterior neck melanoma underwent wide excision and sentinel lymph node dissection 3 years prior to development of distant metastasis. The sentinel lymph node was negative and patient underwent expectant follow up. Patient presented with an episode of abdominal pain 5 months prior to surgery which prompted an evaluation with abdominal CT revealing a 10 cm tumor in the left lobe of the liver with adjacent retroperitoneal adenopathy (Figure 1). CT guided biopsy of the liver lesion showed metastatic melanoma, B-Raf mutated.

carcinogenesis-mutagenesis-Liver-lesion

Figure 1: Liver lesion before treatment with Vemurafenib measuring 10.8 x 9.9 cm.

The patient was started on Vemurafenib (marketed as Zelboraf). Restaging CT scan 4 months after neoadjuvant Vemurafenib showed significant shrinkage of the liver lesion from 10.8 X 9.9 cm to 3.9 X 3.0 cm as well as significant shrinkage of the adjacent retroperitoneal adenopathy (Figure 2). There was no additional site of disease. The patient subsequently underwent left hepatectomy, retroperitoneal lymph node dissection including periportal and celiac nodes.

carcinogenesis-mutagenesis-Liver-lesion-treatment

Figure 2: Liver lesion after treatment with Vemurafenib measuring 3.9 X 3.0 cm.

Surgical pathology showed the liver metastasis measuring 4.5 X 4 X 2.6 cm. Histologically, the tumor showed extensive necrosis with less than of 10% viable cells (Figure 3). Tumor bed was replaced by melanin-pigment laden macrophages consistent with treatment effect of Vemurafenib (Figure 4). Periportal and celiac lymph nodes did not show viable tumor cells (Figure 5).

carcinogenesis-mutagenesis-malignant-melanoma

Figure 3: Focus of rare malignant melanoma cells from the liver lesion.

carcinogenesis-mutagenesis-Pigmented-macrophages

Figure 4: Pigmented macrophages in liver lesion.

carcinogenesis-mutagenesis-pigmented-macrophages

Figure 5: Lymph node with pigmented macrophages.

Discussion

Metastatic melanoma to the liver is an aggressive disease with median survival of 6 months [7]. Improved survival is associated with liver resection. However not all hepatic lesions are easily resectable.

Vemurafenib is a potent selective inhibitor of B-Raf protein with V600E mutation. It has been shown to improve patient survival in phase III clinical trial [5]. It is currently approved for the treatment of unresectable or metastatic melanoma. It has been shown in multiple cases to induce significant metastatic melanoma tumor shrinkage and often complete regression of the gross tumor [8]. However, the response was not durable with median response time of 6.7 months and most responding patient had progression of disease after initial clinical response [5,8]. Therefore, vemurafenib is proposed to be a promising neoadjuvant agent prior to surgical resection of otherwise unresectable or borderline resectable disease.

Review of literature revealed four reports of neoadjuvant Vemurafenib in the setting of borderline resectable metastatic melanoma. Fadaki et al. [9] first reported a case of melanoma involving the left axilla and neck treated with vemurafenib to achieve 50% reduction in tumor size enabling a modified radical neck and axillary dissection. Koers et al. [10] reported a case of axillary lymph node metastasis that was treated with 28-day cycle of vemurafenib to allow an axillary lymph node dissection. The third case [11] was a metastatic melaonoma to the brain, which due to its size precluded stereotactic radiosurgery. After treatment with vemurafenib, the patient received complete resection of the mass. The fourth case [6] was a patient with metastatic melanoma to the left axillary lymph node and brain. Pathology from the surgical resection after vemurafenib treatment showed complete tumor necrosis for both brain and axillary lymph node metastasis.

Our report is the first case of metastatic melanoma to the liver and retroperitoneal lymph node treated with neoadjuvant vemurafenib prior to surgery. Our patient was found to have more than 90% tumor cell reduction in his liver lesion as well as complete tumor necrosis in his periaortic and celiac lymph nodes upon histologic evaluation of his left hepatectomy and retroperitoneal lymphadenectomy specimens.

In conclusion, vemurafenib is a promising agent as neoadjuvant therapy in metastatic melanoma. This report supports further evaluation of the targeted therapy to reduce tumor burden in patients with otherwise unrespectable or borderline resectable metastatic melanoma.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 12001
  • [From(publication date):
    May-2014 - Nov 19, 2017]
  • Breakdown by view type
  • HTML page views : 8227
  • PDF downloads : 3774
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords